CTOs on the Move

Bactolac Pharmaceutical Inc

www.bactolac.com

 
We are completely committed to the success of every one of our client-partners and dedicate ourselves to quality and efficiency. We provide custom formulation and quality manufacturing for your existing formulas and welcome the opportunity to provide
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Mayne Pharma

Mayne Pharma is a fast growing company, focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, with operations in Australia and the US. The Company has grown substantially and reflects the hard work and de...

Qosina

Qosina is one of the leading medical device component suppliers of OEM components to medical and pharmaceutical industries. Explore our products today.

Optinose

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. We have initiated two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and expect top-line results by the end of 2021 from one trial and in the first half of 2022 from the second trial. If successful, we believe XHANCE would be the first drug therapy product approved by the FDA for the treatment of chronic sinusitis. As of February 28, 2021, we had a total of 204 full-time employees and three part-time employees. A majority of our employees are field-based, in customer-facing roles. Culture is a critical element in the management of our organization. Our talented employees, known as colleagues, are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

MIDi

MIDi is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kyowa Hakko Kirin Pharma

Kyowa Hakko Kirin Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.